Discontinuation of beta-blockers and the risk of myocardial infarction in the elderly.

Abstract:

BACKGROUND:It has been shown that the abrupt cessation of treatment with beta-adrenoceptor antagonists (beta-blockers) increases the risk of myocardial infarction in patients with hypertension. As beta-blockers differ in their pharmacokinetic and pharmacodynamic properties, this risk of discontinuation might also differ between subgroups of beta-blockers. OBJECTIVE:To determine whether discontinuation of beta-blockers is associated with an increased risk of myocardial infarction in elderly patients and whether the effects of recent cessation differs between subgroups of beta-blockers, categorised according to their selectivity, lipophilic profile and intrinsic sympathomimetic activity (ISA). DESIGN:A cohort study in users of beta-blockers within the Rotterdam Study, which was a prospective population-based follow-up study of 7983 individuals aged >or=55 years. PATIENTS:We identified 2588 individuals who had been treated with a beta-blocker for at least 30 days at any time during the study period of 1 January 1991 to 1 January 2002. In this group, 148 subjects developed incident myocardial infarction. METHODS:Detailed information on the medication use and clinical characteristics of all patients were collected from the files of pharmacies, general practices and hospitals. Myocardial infarction was diagnosed on the basis of internationally accepted criteria and verified by a cardiologist. The duration of beta-blocker use was calculated from computerised pharmacy records on the basis of the number of dispensed tablets or capsules and the prescribed daily number. For every individual, on the index date (date of myocardial infarction in cases, the same date in controls [defined as any patient who had not experienced a myocardial infarction up to that timepoint]) the usage of beta-blockers was determined and classified as either current or as past use. Past use was classified into three different periods: cessation of beta-blockers less than 30 days; between 30 and 180 days; and more than 180 days before the index date. The risk of myocardial infarction in the three periods of cessation of exposure were analysed using a Cox proportional hazards model that included potential confounders and cardiac co-medication. These analyses were performed for the whole group and for subgroups of beta-blockers. RESULTS:Discontinuation of any beta-blocker was not associated with an increased risk of myocardial infarction compared with current use of a beta-blocker. Analyses within subgroups showed that discontinuation of selective beta-blockers was associated with an increased risk of myocardial infarction compared with current use of any beta-blocker within the first 30 days (relative risk [RR] 2.70; 95% CI 1.06, 6.89) and also between 30 and 180 days after discontinuation (RR 2.44; 95% CI 1.07, 5.59). No increased risk was demonstrated in the other beta-blocker subgroups. CONCLUSION:Overall, discontinuation of beta-blockers was not associated with an increased risk of myocardial infarction. However, when analysed by beta-blocker subgroup, cessation of selective beta-blockers was associated with an increased risk of myocardial infarction during the first 180 days after discontinuation.

journal_name

Drug Saf

journal_title

Drug safety

authors

Teichert M,de Smet PA,Hofman A,Witteman JC,Stricker BH

doi

10.2165/00002018-200730060-00008

subject

Has Abstract

pub_date

2007-01-01 00:00:00

pages

541-9

issue

6

eissn

0114-5916

issn

1179-1942

pii

3068

journal_volume

30

pub_type

临床试验,杂志文章
  • Adverse effects of monobactams and carbapenems.

    abstract::Monobactams and carbapenems are 2 classes of beta-lactam antibiotics that were introduced in the 1980s. This review considers the monobactam aztreonam and the carbapenems imipenem and meropenem. Imipenem is administered together with cilastatin, which inhibits the enzymatic breakdown of imipenem in the kidney. The ant...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199512050-00003

    authors: Alván G,Nord CE

    更新日期:1995-05-01 00:00:00

  • Complications of regional anaesthesia Incidence and prevention.

    abstract::The complications of failure, neural injury and local anaesthetic toxicity are common to all regional anaesthesia techniques, and individual techniques are associated with specific complications. All potential candidates for regional anaesthesia should be thoroughly evaluated and informed of potential complications. I...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200124060-00002

    authors: Faccenda KA,Finucane BT

    更新日期:2001-01-01 00:00:00

  • Antidepressants and the Risk of Hemorrhagic Stroke in the Elderly: a Nested Case-Control Study.

    abstract:BACKGROUND AND PURPOSE:Selective serotonin reuptake inhibitors (SSRIs) are frequently prescribed in the elderly due to a more favorable risk profile than other antidepressants (ADs). However, SSRIs are associated with an increased risk of gastrointestinal bleeding, while evidence on the risk of hemorrhagic stroke (HS) ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-019-00837-y

    authors: Schäfer W,Princk C,Kollhorst B,Schink T

    更新日期:2019-09-01 00:00:00

  • Risk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies.

    abstract::Since 2008, the direct-acting oral anticoagulants (DOACs) have expanded the therapeutic options of cardiovascular diseases with recognized clinical and epidemiological impact, such as non-valvular atrial fibrillation (NVAF) and venous thromboembolism (VTE), and also in the preventive setting of orthopedic surgical pat...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-016-0464-3

    authors: Raschi E,Bianchin M,Ageno W,De Ponti R,De Ponti F

    更新日期:2016-12-01 00:00:00

  • Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre.

    abstract:BACKGROUND:Rituximab is a monoclonal antibody approved for treating CD20-positive B-cell non-Hodgkin's lymphoma and rheumatoid arthritis but is used off-label for treating many autoimmune disorders, including multiple sclerosis (MS). Similarly to other monoclonal antibodies, the incidence of infusion-related reactions ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11585960-000000000-00000

    authors: Brown BA,Torabi M

    更新日期:2011-02-01 00:00:00

  • Prospective data mining of six products in the US FDA Adverse Event Reporting System: disposition of events identified and impact on product safety profiles.

    abstract:BACKGROUND:The use of data mining has increased among regulators and pharmaceutical companies. The incremental value of data mining as an adjunct to traditional pharmacovigilance methods has yet to be demonstrated. Specifically, the utility in identifying new safety signals and the resources required to do so have not ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11319000-000000000-00000

    authors: Bailey S,Singh A,Azadian R,Huber P,Blum M

    更新日期:2010-02-01 00:00:00

  • Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis.

    abstract:BACKGROUND:An association between oral contraceptive (OC) use and venous thromboembolism (VTE) has long been recognized. However, no summary estimates of the increase in VTE risk associated with OC use have been available since 1995, and no meta-analyses have evaluated the VTE risk of new preparations containing drospi...

    journal_title:Drug safety

    pub_type: 杂志文章,meta分析,评审

    doi:10.2165/11598050-000000000-00000

    authors: Manzoli L,De Vito C,Marzuillo C,Boccia A,Villari P

    更新日期:2012-03-01 00:00:00

  • A Novel Approach to Visualize Risk Minimization Effectiveness: Peeping at the 2012 UK Proton Pump Inhibitor Label Change Using a Rapid Cycle Analysis Tool.

    abstract:INTRODUCTION:Evaluation of risk minimization (RM) actions is an emerging area of regulatory science, often without tools to rapidly and systematically assess their effectiveness. PURPOSE:The aim of this study was to evaluate whether chronographs, typically used for rapid signal detection in observational longitudinal ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-019-00853-y

    authors: Sobel RE,Blackwell W,Fram DM,Bate A

    更新日期:2019-11-01 00:00:00

  • Intentional rechallenge: does the benefit outweigh the risk?

    abstract::Rechallenge is defined as the readministration of a medication suspected of being a possible cause of an adverse reaction and which has been discontinued as result. It may be unintentional when the appearance of a reaction was initially not attributed to the medication. A rechallenge may be intentional when a prescrib...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-013-0020-3

    authors: Stanulović V,Venegoni M,Edwards B

    更新日期:2013-03-01 00:00:00

  • Tolerabilities of antiretrovirals in paediatric HIV infection.

    abstract::Data on the efficacy and tolerability of antiretrovirals in children are limited as, in contrast to adult studies, large paediatric cohort studies are lacking. Thus, data pertaining to adults are often extrapolated to children despite the acknowledgement that children are not little adults. This review summarises info...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200225140-00001

    authors: Lemberg DA,Palasanthiran P,Goode M,Ziegler JB

    更新日期:2002-01-01 00:00:00

  • Quinolones: review of psychiatric and neurological adverse reactions.

    abstract::Quinolones are a class of antibacterial agents for the treatment of several infectious diseases (e.g. urinary and respiratory tract infections). They are used worldwide due to their broad spectrum of activity, high bioavailability and good safety profile. The safety profile varies from quinolone to quinolone. The aim ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/11587280-000000000-00000

    authors: Tomé AM,Filipe A

    更新日期:2011-06-01 00:00:00

  • Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

    abstract::Cholinesterase inhibitors are currently the most established treatment strategy in Alzheimer's disease. The treatment effect appears mainly to be symptomatic. Effects on progression of the disease following long term treatment, and possible neuroprotective effects, have been investigated. Delay until nursing home plac...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199819060-00004

    authors: Nordberg A,Svensson AL

    更新日期:1998-12-01 00:00:00

  • Risks and benefits of soy phytoestrogens in cardiovascular diseases, cancer, climacteric symptoms and osteoporosis.

    abstract::Phytoestrogens, plant chemicals classified as isoflavones, coumestans and lignans, display estrogen-like activity because of their structural similarity to human estrogens and exhibit high affinity binding for the estrogen receptor beta. They are common components of food items such as grains, beans, fruits and nuts. ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200124090-00003

    authors: Sirtori CR

    更新日期:2001-01-01 00:00:00

  • Safety and Tolerability of Adoptive Cell Therapy in Cancer.

    abstract::Adoptive T cell therapy (ACT) is a safe and effective personalized cancer immunotherapy that can comprise naturally occurring ex vivo expanded cells (e.g., tumor-infiltrating lymphocytes [TIL]) or T cells genetically engineered to confer antigen specificity (T-cell receptor [TCR] or chimeric antigen receptor [CAR] eng...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-018-0779-3

    authors: Wolf B,Zimmermann S,Arber C,Irving M,Trueb L,Coukos G

    更新日期:2019-02-01 00:00:00

  • Randomized controlled trials of COX-2 inhibitors: an analysis of doses used and trends over time to investigate implications for comparative safety.

    abstract:BACKGROUND:Naproxen, ibuprofen and diclofenac are frequently used as comparators in randomized controlled trials (RCTs) on the safety and efficacy of cyclooxygenase (COX)-2 inhibitors. Different comparator doses may influence the results of RCTs. It has been hypothesized that RCTs of COX-2 inhibitors where different do...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11590470-000000000-00000

    authors: Stefansdottir G,De Bruin ML,Knol MJ,Grobbee DE,Leufkens HG

    更新日期:2011-09-01 00:00:00

  • Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review.

    abstract::After 2002, an association between stroke and antipsychotic use was reported in clinical trials and large database studies. This review considers previous quantitative reviews, newly published clinical trials, and recent observational cohort and case-control studies, and focuses on the clinical significance of the ris...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/11319120-000000000-00000

    authors: Sacchetti E,Turrina C,Valsecchi P

    更新日期:2010-04-01 00:00:00

  • Drugs dispensed in primary care during pregnancy: a record-linkage analysis in Tayside, Scotland.

    abstract:BACKGROUND:For many regularly used drugs, evidence for safe use in pregnancy has not been established. Despite this, international studies have identified high levels of drug prescribing among pregnant women. OBJECTIVE:To investigate the patterns of prescribing of drugs to women who gave birth in Tayside, Scotland, in...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11532330-000000000-00000

    authors: Irvine L,Flynn RW,Libby G,Crombie IK,Evans JM

    更新日期:2010-07-01 00:00:00

  • Skin sensitivity and transdermal drug delivery. A review of the problem.

    abstract::Transdermal devices are now marketed for the delivery of systemic medication through the skin. Advantages associated with transdermal drug delivery include avoidance of first-pass metabolism and improved patient compliance. Drugs currently available by this route include scopolamine (hyoscine), nitroglycerin (glyceryl...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199410020-00004

    authors: Carmichael AJ

    更新日期:1994-02-01 00:00:00

  • Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster.

    abstract::The biologics have revolutionized the treatment of rheumatoid arthritis (RA). However, there are still patients that are difficult to control and a cure is still not achievable. Tofacitinib, a Janus kinase (JAK) inhibitor is an orally available, new-in-class, disease-modifying anti-rheumatic drug with similar efficacy...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-016-0430-0

    authors: Yamaoka K

    更新日期:2016-09-01 00:00:00

  • Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update.

    abstract::The risk of coronary events with non-steroidal anti-inflammatory drugs has been the subject of much debate since the original trial of rofecoxib raised the issue. Since then, over almost 20 years, such risks have been shown in clinical trials of long-term high-dose users, and in observational studies comparing users w...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-019-00900-8

    authors: Moore N

    更新日期:2020-04-01 00:00:00

  • Vancomycin-Induced Thrombocytopenia: A Narrative Review.

    abstract::Thrombocytopenia has been reported as an adverse reaction of numerous drugs. Vancomycin is often overlooked as a culprit but has been associated with several cases of thrombocytopenia that were not well described in the literature. A literature search was conducted to find reports of thrombocytopenia induced by vancom...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-016-0469-y

    authors: Mohammadi M,Jahangard-Rafsanjani Z,Sarayani A,Hadjibabaei M,Taghizadeh-Ghehi M

    更新日期:2017-01-01 00:00:00

  • A benefit-risk assessment of misoprostol for cervical ripening and labour induction.

    abstract::Misoprostol, a prostaglandin E(1) analogue, is widely used in the US and other countries for cervical ripening and labour induction. Its use for these indications is not approved by the US Food and Drug Administration (FDA). The manufacturer of misoprostol issued a letter to American healthcare providers in August 200...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200225090-00005

    authors: Wing DA

    更新日期:2002-01-01 00:00:00

  • Dopamine Agonists and Impulse Control Disorders: A Complex Association.

    abstract::Impulse control disorders (ICDs) are a well-known adverse effect of dopamine agonists (DAAs). This critical review aims to summarize data on the prevalence and factors associated with the development of an ICD simultaneous to DAA use. A search of two electronic databases was completed from inception to July 2017. The ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-017-0590-6

    authors: Grall-Bronnec M,Victorri-Vigneau C,Donnio Y,Leboucher J,Rousselet M,Thiabaud E,Zreika N,Derkinderen P,Challet-Bouju G

    更新日期:2018-01-01 00:00:00

  • The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases.

    abstract::All national guidelines for the management of hypertension recommend angiotensin receptor blockers (ARBs) as an initial or add-on antihypertensive therapy. The eight available ARBs have variable clinical efficacy when used for control of hypertension. Additive blood pressure-lowering effects have been demonstrated whe...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-014-0239-7

    authors: Abraham HM,White CM,White WB

    更新日期:2015-01-01 00:00:00

  • All-Cause Mortality Associated with Tramadol Use: A Case-Crossover Study.

    abstract:INTRODUCTION:Although the mortality risk associated with tramadol use in children has triggered the revision of tramadol drug labeling, the mortality risk in adults has not been thoroughly explored. OBJECTIVE:The objective of this study was to evaluate whether tramadol use is associated with mortality in various risk ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-018-00786-y

    authors: Jeong S,Tchoe HJ,Li J,Shin JY

    更新日期:2019-06-01 00:00:00

  • Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study.

    abstract:BACKGROUND:While cases of amyotrophic lateral sclerosis (ALS) or ALS-like conditions have arisen in apparent association with HMG-CoA reductase inhibitors ('statins') and/or other lipid-lowering drugs (collectively termed 'statins' in this paper for brevity), additional information is needed to understand whether the c...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200932080-00004

    authors: Golomb BA,Kwon EK,Koperski S,Evans MA

    更新日期:2009-01-01 00:00:00

  • Epidemiology of adverse drug reactions in Europe: a review of recent observational studies.

    abstract::Adverse drug reactions (ADRs) cause considerable mortality and morbidity but no recent reviews are currently available for the European region. Therefore, we performed a review of all epidemiological studies quantifying ADRs in a European setting that were published between 1 January 2000 and 3 September 2014. Include...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-015-0281-0

    authors: Bouvy JC,De Bruin ML,Koopmanschap MA

    更新日期:2015-05-01 00:00:00

  • Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003.

    abstract:BACKGROUND:Clozapine is an antipsychotic medication associated with a lower suicide rate compared with other antipsychotic agents. Clozapine is used specifically in patients for whom previous therapy was inadequate or not tolerated, and is the only antipsychotic agent associated with the development of myocarditis. OB...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200730010-00005

    authors: Haas SJ,Hill R,Krum H,Liew D,Tonkin A,Demos L,Stephan K,McNeil J

    更新日期:2007-01-01 00:00:00

  • Pain treatment in multimorbid patients, the older population and other high-risk groups. The clinical challenge of reducing toxicity.

    abstract::The prevalence of pain is high in multimorbid patients and they can experience a multitude of painful conditions. The changes in physiology and homeostasis associated with multimorbidity and increasing age and the immature metabolism of neonates all increase the risk of toxicity from analgesics. Altered pharmacokineti...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199818060-00006

    authors: Wilder-Smith CH

    更新日期:1998-06-01 00:00:00

  • Detection of adverse drug events and other treatment outcomes using an electronic prescribing system.

    abstract:BACKGROUND:Current pharmacosurveillance methods do not provide timely information on drug safety and effectiveness. Real-time surveillance using electronic prescribing systems could address this problem; however, the data collected using these systems has not been validated. We investigated the accuracy of using orders...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200831110-00005

    authors: Eguale T,Tamblyn R,Winslade N,Buckeridge D

    更新日期:2008-01-01 00:00:00